ArticleEndocrine journal2025
Establishment of novel prognostic groups for papillary thyroid carcinoma using a modified risk classification based on tumor extension in the guidelines of the Japan Association of Endocrine Surgery.
Article in Endocrine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest "General Rules for the Description of Thyroid Cancer," published in 2023, introduced depth-based subcategories of tumor invasion, dividing sEx2 into sEx2a, sEx2b, and sEx3. However, the "Clinical Guidelines on the Management of Thyroid Tumors," published in 2024, continue to classify these categories uniformly as high-risk for papillary thyroid carcinoma (PTC). We evaluated the appropriateness of reclassifying sEx2a-high-risk patients as intermediate-risk. A total of 9,247 patients [median age: 52 years (7-93)] who underwent locally curative surgery were enrolled, with a median follow-up of 7.8 years. Cause-specific survival (CSS), distant recurrence-free survival (DR-FS), and local recurrence-free survival (LR-FS) worsened progressively from low-risk to high-risk patients. We compared the prognoses among the patients classified as sEx2a-high-risk, sEx2b, and intermediate-risk. The CSS, DR-FS, and LR-FS outcomes of sEx2b patients were significantly poorer than those of sEx2a-high-risk and intermediate-risk patients. By reclassifying sEx2a-high-risk patients as intermediate-risk, we established a new high-risk and intermediate-risk classification. The number of high-risk patients decreased from 2,274 to 1,132, whereas the number of intermediate-risk patients increased from 2,875 to 4,017. Prognoses in these new groups showed minimal differences compared to the original high- and intermediate-risk classifications. We established novel prognostic groups: favorable (N = 6,398, low-risk and intermediate-risk <55 years), intermediate (N = 2,324, intermediate-risk ≥55 years and high-risk <55 years), and poor (N = 525, high-risk ≥55 years). Prognoses significantly worsened across these groups from favorable to poor (p < 0.001). The reclassification of PTC based on tumor extension and the proposed novel prognostic groups provide a more accurate evaluation of PTC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.